WO2022112806A2 - Food supplement or medicinal or pharmaceutical composition inhibiting virus infection, advantageously infection of sars-cov-2 and ibv coronaviruses and formulation thereof - Google Patents
Food supplement or medicinal or pharmaceutical composition inhibiting virus infection, advantageously infection of sars-cov-2 and ibv coronaviruses and formulation thereof Download PDFInfo
- Publication number
- WO2022112806A2 WO2022112806A2 PCT/HU2021/000014 HU2021000014W WO2022112806A2 WO 2022112806 A2 WO2022112806 A2 WO 2022112806A2 HU 2021000014 W HU2021000014 W HU 2021000014W WO 2022112806 A2 WO2022112806 A2 WO 2022112806A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methyl
- composition according
- formulation
- arginine
- acceptors
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 57
- 238000009472 formulation Methods 0.000 title claims abstract description 20
- 235000015872 dietary supplement Nutrition 0.000 title claims abstract description 7
- 230000009385 viral infection Effects 0.000 title claims abstract description 7
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 6
- 208000015181 infectious disease Diseases 0.000 title claims description 5
- 241000711573 Coronaviridae Species 0.000 title claims description 3
- 230000002401 inhibitory effect Effects 0.000 title description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 75
- 239000000370 acceptor Substances 0.000 claims abstract description 26
- 150000001875 compounds Chemical class 0.000 claims abstract description 15
- 238000000034 method Methods 0.000 claims abstract description 13
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 13
- 230000011987 methylation Effects 0.000 claims abstract description 12
- 238000007069 methylation reaction Methods 0.000 claims abstract description 12
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 11
- 239000002207 metabolite Substances 0.000 claims abstract description 6
- 229920002521 macromolecule Polymers 0.000 claims abstract description 5
- 208000025721 COVID-19 Diseases 0.000 claims abstract description 4
- -1 methyl (hydroxy methyl ) groups Chemical group 0.000 claims abstract description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 63
- 229960005070 ascorbic acid Drugs 0.000 claims description 29
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 25
- 229930064664 L-arginine Natural products 0.000 claims description 22
- 235000014852 L-arginine Nutrition 0.000 claims description 21
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 16
- 235000000069 L-ascorbic acid Nutrition 0.000 claims description 13
- 239000002211 L-ascorbic acid Substances 0.000 claims description 13
- 230000008569 process Effects 0.000 claims description 10
- 235000018102 proteins Nutrition 0.000 claims description 10
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 9
- 239000000126 substance Substances 0.000 claims description 8
- 239000004480 active ingredient Substances 0.000 claims description 7
- 239000004615 ingredient Substances 0.000 claims description 7
- 239000007787 solid Substances 0.000 claims description 7
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 6
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims description 6
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 claims description 6
- WWNNZCOKKKDOPX-UHFFFAOYSA-N N-methylnicotinate Chemical compound C[N+]1=CC=CC(C([O-])=O)=C1 WWNNZCOKKKDOPX-UHFFFAOYSA-N 0.000 claims description 6
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
- 229920002472 Starch Polymers 0.000 claims description 6
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 6
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims description 6
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 239000002994 raw material Substances 0.000 claims description 6
- 239000008107 starch Substances 0.000 claims description 6
- 235000019698 starch Nutrition 0.000 claims description 6
- 239000001913 cellulose Substances 0.000 claims description 5
- 235000010980 cellulose Nutrition 0.000 claims description 5
- 229920002678 cellulose Polymers 0.000 claims description 5
- QWJSAWXRUVVRLH-UHFFFAOYSA-M choline bitartrate Chemical compound C[N+](C)(C)CCO.OC(=O)C(O)C(O)C([O-])=O QWJSAWXRUVVRLH-UHFFFAOYSA-M 0.000 claims description 5
- 229960004874 choline bitartrate Drugs 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 239000000047 product Substances 0.000 claims description 5
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 claims description 4
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 claims description 4
- MXNRLFUSFKVQSK-QMMMGPOBSA-O N(6),N(6),N(6)-trimethyl-L-lysine Chemical compound C[N+](C)(C)CCCC[C@H]([NH3+])C([O-])=O MXNRLFUSFKVQSK-QMMMGPOBSA-O 0.000 claims description 4
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims description 4
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims description 4
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 claims description 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 3
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 3
- 229930195725 Mannitol Natural products 0.000 claims description 3
- 235000021355 Stearic acid Nutrition 0.000 claims description 3
- 229930006000 Sucrose Natural products 0.000 claims description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 3
- 229960003237 betaine Drugs 0.000 claims description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 3
- 239000000969 carrier Substances 0.000 claims description 3
- 239000000905 isomalt Substances 0.000 claims description 3
- 235000010439 isomalt Nutrition 0.000 claims description 3
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- 229960001375 lactose Drugs 0.000 claims description 3
- 229960001021 lactose monohydrate Drugs 0.000 claims description 3
- 235000019359 magnesium stearate Nutrition 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- 235000010355 mannitol Nutrition 0.000 claims description 3
- 230000004048 modification Effects 0.000 claims description 3
- 238000012986 modification Methods 0.000 claims description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 3
- 239000000377 silicon dioxide Substances 0.000 claims description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 3
- 239000011780 sodium chloride Substances 0.000 claims description 3
- 239000008117 stearic acid Substances 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- 239000000454 talc Substances 0.000 claims description 3
- 229910052623 talc Inorganic materials 0.000 claims description 3
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 claims description 2
- 108010024636 Glutathione Proteins 0.000 claims description 2
- FFFHZYDWPBMWHY-UHFFFAOYSA-N L-Homocysteine Natural products OC(=O)C(N)CCS FFFHZYDWPBMWHY-UHFFFAOYSA-N 0.000 claims description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 2
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 claims description 2
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims description 2
- 239000012298 atmosphere Substances 0.000 claims description 2
- 239000007963 capsule composition Substances 0.000 claims description 2
- 239000004202 carbamide Substances 0.000 claims description 2
- 235000013877 carbamide Nutrition 0.000 claims description 2
- 235000012754 curcumin Nutrition 0.000 claims description 2
- 239000004148 curcumin Substances 0.000 claims description 2
- 229940109262 curcumin Drugs 0.000 claims description 2
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims description 2
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 claims description 2
- 238000005538 encapsulation Methods 0.000 claims description 2
- NLDDIKRKFXEWBK-AWEZNQCLSA-N gingerol Chemical compound CCCCC[C@H](O)CC(=O)CCC1=CC=C(O)C(OC)=C1 NLDDIKRKFXEWBK-AWEZNQCLSA-N 0.000 claims description 2
- JZLXEKNVCWMYHI-UHFFFAOYSA-N gingerol Natural products CCCCC(O)CC(=O)CCC1=CC=C(O)C(OC)=C1 JZLXEKNVCWMYHI-UHFFFAOYSA-N 0.000 claims description 2
- 235000002780 gingerol Nutrition 0.000 claims description 2
- 229960003180 glutathione Drugs 0.000 claims description 2
- 229960001340 histamine Drugs 0.000 claims description 2
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 2
- 229960003512 nicotinic acid Drugs 0.000 claims description 2
- 235000001968 nicotinic acid Nutrition 0.000 claims description 2
- 239000011664 nicotinic acid Substances 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- 239000004033 plastic Substances 0.000 claims description 2
- 235000021283 resveratrol Nutrition 0.000 claims description 2
- 229940016667 resveratrol Drugs 0.000 claims description 2
- 239000008247 solid mixture Substances 0.000 claims description 2
- 239000000243 solution Substances 0.000 claims description 2
- 206010064097 avian influenza Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 150000002894 organic compounds Chemical class 0.000 abstract description 4
- 208000001528 Coronaviridae Infections Diseases 0.000 abstract description 3
- 230000017693 oxidative demethylation Effects 0.000 abstract description 3
- 238000007067 oxidative demethylation reaction Methods 0.000 abstract description 3
- 238000012546 transfer Methods 0.000 abstract description 3
- 125000005842 heteroatom Chemical group 0.000 abstract description 2
- 208000036142 Viral infection Diseases 0.000 abstract 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 21
- 229960001231 choline Drugs 0.000 description 21
- 235000010323 ascorbic acid Nutrition 0.000 description 17
- 239000011668 ascorbic acid Substances 0.000 description 17
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 16
- 239000004475 Arginine Substances 0.000 description 14
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 14
- 235000009697 arginine Nutrition 0.000 description 14
- 230000000694 effects Effects 0.000 description 12
- 230000004060 metabolic process Effects 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 201000010099 disease Diseases 0.000 description 10
- 230000006870 function Effects 0.000 description 9
- 241000282414 Homo sapiens Species 0.000 description 8
- 208000024827 Alzheimer disease Diseases 0.000 description 7
- 230000003078 antioxidant effect Effects 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 230000018109 developmental process Effects 0.000 description 7
- 230000036542 oxidative stress Effects 0.000 description 7
- 239000003963 antioxidant agent Substances 0.000 description 6
- 235000006708 antioxidants Nutrition 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 102000004452 Arginase Human genes 0.000 description 5
- 108700024123 Arginases Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 230000017858 demethylation Effects 0.000 description 5
- 238000010520 demethylation reaction Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 5
- 206010010904 Convulsion Diseases 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 3
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000003511 endothelial effect Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000009469 supplementation Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 208000004481 Choline Deficiency Diseases 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- 150000000996 L-ascorbic acids Chemical class 0.000 description 2
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 2
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 2
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 2
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000009134 cell regulation Effects 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 208000021752 choline deficiency disease Diseases 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229960004452 methionine Drugs 0.000 description 2
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 229960003104 ornithine Drugs 0.000 description 2
- 230000007310 pathophysiology Effects 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 230000001457 vasomotor Effects 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- QYPPJABKJHAVHS-UHFFFAOYSA-N Agmatine Natural products NCCCCNC(N)=N QYPPJABKJHAVHS-UHFFFAOYSA-N 0.000 description 1
- 102000001049 Amyloid Human genes 0.000 description 1
- 108010094108 Amyloid Proteins 0.000 description 1
- 208000006770 Ascorbic Acid Deficiency Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 230000007067 DNA methylation Effects 0.000 description 1
- 206010048554 Endothelial dysfunction Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- 229930195722 L-methionine Natural products 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001502129 Mullus Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 241000219492 Quercus Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 241001024096 Uleiota Species 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 206010047623 Vitamin C deficiency Diseases 0.000 description 1
- 230000036579 abiotic stress Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000004849 abnormal protein aggregation Effects 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- QYPPJABKJHAVHS-UHFFFAOYSA-P agmatinium(2+) Chemical compound NC(=[NH2+])NCCCC[NH3+] QYPPJABKJHAVHS-UHFFFAOYSA-P 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000035 biogenic effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000004790 biotic stress Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000032677 cell aging Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000007960 cellular response to stress Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000007267 depressive like behavior Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- BADXJIPKFRBFOT-UHFFFAOYSA-N dimedone Chemical compound CC1(C)CC(=O)CC(=O)C1 BADXJIPKFRBFOT-UHFFFAOYSA-N 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 208000002161 echolalia Diseases 0.000 description 1
- 230000008694 endothelial dysfunction Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000008175 fetal development Effects 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 230000004179 hypothalamic–pituitary–adrenal axis Effects 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 1
- 230000010262 intracellular communication Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000003695 memory enhancer Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 235000006109 methionine Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000003227 neuromodulating effect Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000005868 ontogenesis Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 230000037074 physically active Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 230000004845 protein aggregation Effects 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000010666 regulation of catalytic activity Effects 0.000 description 1
- 230000028981 regulation of cellular metabolic process Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000011808 rodent model Methods 0.000 description 1
- 208000010233 scurvy Diseases 0.000 description 1
- 229960001153 serine Drugs 0.000 description 1
- 235000004400 serine Nutrition 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000006032 tissue transformation Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000004143 urea cycle Effects 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000005727 virus proliferation Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Definitions
- Food supplement or medicinal or pharmaceutical composition inhibiting virus infection, advantageously infection of SARS- COV-2 and IBV coronaviruses and formulation thereof
- the subject matter of the invention is a multi-component, advantageously two or three component food supplement or medicinal or pharmaceutical composition
- a multi-component, advantageously two or three component food supplement or medicinal or pharmaceutical composition comprising easy mobilizable methyl groups for use in reducing virus infection advantageously infection of SARS-CGV-2 and IBV coronaviruses by changing the "set" of methyl groups of the body and the methylation level of cells by the modification of methylation level of metabolites, macromolecules, proteins, RNA, DNA in the transmethylation cycle of the cells, comprising at least one methyl donor advantageously the following and/or related compounds :
- L-carnitine 541-15-1 and at least one methyl acceptor advantageously the following and/or related compounds:
- Carbamide 57-13-6 in such a way that the quotient of molar ratio of the methyl donors and methyl acceptors is higher than "one "and is in 4:1,5 range of molar ratio, advantageously corresponds to 3:2 molar ratio.
- the subject matter of the invention is for use in reducing of the worldwide spread COVID-19 coronavirus infection.
- Methyl donor compounds Organic compounds methylated on their N-, S- and 0 heteroatoms where methyl groups thereof transfer into transmethylation cycle after oxidative demethylation.
- Methyl acceptor compounds Organic compounds for use in binding methyl (hydroxy methyl) groups.
- antioxidant capacity the study of endogenous transmethylation, the methyiation level of living organisms and the physiological effect of the methyl donor compounds in the methyiation cycle, their role in the metabolic process of the body, its regulation, in the supervision of the function of different genes get more and more into the centre of attention.[Corbin and Zeisel, 2012].
- SAM S-adenosyl-L-methionine
- Methyl donors are directly or indirectly involved in the methyiation cycle, however, nucleic acids, proteins, peptides, amino acids, biogenic amines, nor-alkaloids, etc. can be used as acceptor molecules in enzymatic transmethylation reactions. Material quality distribution and quantitative changes of donors and acceptors characterize the physiological state of the biological system. [Sardi and Tyihak, 1998]
- choline has been shown to inhibit cholesterol deposition, to aid metabolism, to use of fatty acids, and to detoxify the body, on the other hand, during the metabolism of the brain, choline is converted to acetylcholine, which plays a role in the transmission of stimuli and in the regulation of the function of nerves coordinating memory and muscle movement. [e.g., Yoshimoto et al. 2004).
- Choline deficiency alters DNA methylation and thus gene expression [Zeisel, 2012]. Choline has also been shown to play an important role in fetal development, so a choline-rich diet is especially important during pregnancy. [Medici et al. 2014].
- Betaine an oxidation product of choline, potentiates the detoxifying effect of the liver, helps protect against hepatic steatosis, and is a major player in endogenous transmethylation as a methyl donor.
- Choline is a member of the B-complex, simply because it is not classified as a B-vitamin, because not only can our body get it from an external source, but it can also synthesize it. This requires the involvement of other substances, such as methionine and serine, folic acid, and vitamin B12.
- Choline emulsifies fats and cholesterol, so they do not deposit in the liver, gallbladder, or blood vessel walls.
- As a phosphatidyl-choline it preserves the integrity of the cell membrane, plays a role in the transfer of information, energy supply and intracellular communication between cells, and participates in the preservation of cellular structures and functions.
- acetylcholine During the metabolism of the brain, it is converted to acetylcholine, which plays a role in the transmission of stimuli.
- Adequate choline levels in the brain can provide protection against certain types of dementia, most notably the development of Alzheimer's disease.
- Several studies have also looked at its effects in patients with pre-existing Alzheimer's disease, and in most experiments, choline supplementation has significantly improved patients' memory. [Tiraboschi et al. 2004].
- ascorbic acid acts as an antioxidant in the body. Primarily, it plays a protective role, neutralizing the free radicals that cause ceil damage and mutations due to its antioxidant effect, which causes cell aging or cancerous degeneration. Together with white blood cells, it is involved in protecting the body against infections.
- endothelial vasomotor function is abnormal, the potential mechanism of which is increased oxidative stress.
- Levine et al. (1996) hypothesized that the antioxidant ascorbic acid improves endothelium- dependent arterial dilation in coronary artery disease.
- Ascorbic acid has been shown to reverse endothelial vasomotor dysfunctions in the brachial circulation of patients with coronary artery disease.
- Ascorbic acid contributes to the homeostasis of normal tissues and organs as well as to tissue regeneration. In the brain, ascorbate performs neuromodulatory functions and neutralizes reactive oxygen species formed during synaptic activity and neuronal metabolism. These properties are important because redox imbalance and abnormal protein aggregation play a central role in the pathogenesis of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease and Huntington's disease, multiple sclerosis, and amyotrophic lateral sclerosis. Thus, ascorbic acid is primarily associated with a reduction in oxidative stress and a reduction in the formation of protein aggregates, which may contribute to a reduction in the cognitive and / or motor impairments observed during neurodegenerative processes [Moretti et al. 2017]
- Arginine is a semi-essential amino acid involved in the process of nitric oxide formation, which produces nitric oxide directly through nitric oxide synthase enzymes. It is especially important for certain diseases and chronic conditions, such as high blood pressure and type 2 diabetes, as these conditions are usually characterized by an increase in the enzyme that breaks down L-arginine (arginase), which results in a temporary deficiency; this prevents an increase in blood pressure in these conditions and can be partially remedied by increasing L-arginine intake or resolving the disease / disease state. [Wu and Morris, 1998].
- Arginine is required by our body in several ways. It is involved in the formation of creatine, which also plays an important role in the body - its lack causes mental retardation. It also affects the production of agmatine, which is a signaling molecule in the body and an intermediate in the urea cycle, along with L-ornithine and L-citrulline.
- Arginine helps the body make proteins and stimulates the release of insulin. As part of the nitric oxide cycle, it has several positive effects on physically active people. The effects of arginine are best attributed to its ability to produce nitric oxide, which affects many other processes in the body. Nitric oxide is an important neurotransmitter, it helps to relax the arteries and thus improves blood circulation, thus helping to prevent cardiovascular disease.
- Nitric oxide can stimulate the immune system to fight harmful pathogens.
- Increasing the level of nitric oxide in the body improves immune responses against unwanted bacteria and viruses. [Popovic et al.2007].
- Tan et al. (2009) conducted experiments to test the hypothesis that dietary L-arginine supplementation enhances immunity in early weaned piglets. Based on their results, a dietary supplement made with L-arginine enhanced the cellular and humoral immunity of piglets by modulating the production of leukocytes, cytokines, and antibodies. These results indicate that increasing the amount of L-arginine has a beneficial effect on the optimal immune responses of young pigs and may also have important implications for the development of an improved recipe developed for human infants.
- Arginine is an important modulator of immune activation, often found in immunotherapeutic systems. However, the mechanism by which arginine may have a positive effect in immunotherapy is unknown.
- a study by Bansal and Ochoa (2003) details the importance of arginine, its metabolism, and finally its physiological role in critically ill and immunodeficient patients. It has been found that the availability of arginine in critical disease can be regulated by arginase activity, so arginase expression appears to be essential in the regulation of the cellular immune response and the inflammatory process.
- Arginase plays an important role in the production of precursors of ornithine, proline, and polyamine, all of which are required for cell proliferation and wound healing.
- the components of the formulation containing choline, L- ascorbic acid and L-arginine are potentially useful compounds in the cell transmethylation cycle.
- Transmethylation can modify the level of methylation of metabolites and macromolecules (proteins, RNA, DNA) that are part of the cycle through rearrangement of the methyl groups of the cell (Park et al., 1980; Park and Paik, 1990; Darnell et al., 1986; Khan et al, 1978; Philips, 2008).
- Transmethylation plays a role in eliminating the effects of abiotic and biotic stress (Horvath and van Hasselt, 1985; Sardi and Tyihak, 1998; Laszió et al., 1998; Lin and Pearce, 1990; Mullet and Whitsitt, 1996; Tyihak et al., 1989; Nemeth et al. 1938; Albert et al, 1998).
- Cellular stress responses are reflected in the changes in the amounts of different methyl acceptor and donor metabolites and macromolecules over time (Sardi, 1996),
- the choline (chemical name) component of the composition contains three methyl groups attached to a nitrogen atom. Choline is a methyl donor in transmethylation (Michal, 1993; Hanson et al., 2000; Tyihak et al., 1998). Deterministic changes in choline for the treatment of various stress effects have been demonstrated (Sardi, 2006).
- L-arginine (chemical name) can efficiently take up the methyl groups of a methyl donor through its guanidino-functional group (Le and Fujimori, 2012), and the double-bonded carbon pair of L-ascorbic acid has this chemical property.
- L-arginine and L-ascorbic acid function as methyl acceptors during transmethylation. Methyl acceptors help to regroup methyl groups stored in strong chemical bonds into weaker chemical bonding forms that the ceil can rapidly utilize through targeted methylation to eliminate various stress events.
- arginine and L-ascorbic acid can take up oxidized methyl groups (hydroxymethyl groups) temporarily formed from methyl groups as acceptors in a reaction without enzyme catalysis.
- L- arginine binds oxidized methyl groups at a rate 3-5 times higher than L-ascorbic acid. The ability of these two acceptors to capture oxidized carbon was studied based on their analogous reactions with formaldehyde and examined by FT-IR spectrometry (Fig. 1).
- the two graphs in Figure 1 show a model study of the ability of methyl acceptors (L-arginine, L-ascorbic acid) to capture the oxidized methyl group based on FT-IR spectrometric tracing of methyl acceptors with formaldehyde (1.a. Kinetics of Arginine + HCHO reaction; l.b. K-kinetics of L-ascorbic acid + ECHO reaction).
- the L-arginine content of the formulation induces a decrease in rhe stock of oxidized methyl groups in the cell, compensated by the regulation of transmethylation by intensifying the enzymatic demethylation.
- methyl acceptor dimedone in tissue structure (Sard! 1996; 1998; Laszlo et al., 1998; Nemeth, 2002) was able to increase the amount of oxidized methyl groups in tissues by almost 100%.
- Elevated levels of the arginine-induced demethylation process of transmethylation fmetabolism are expected to be stabilized by the slow "stealing" role of L-ascorbic acid.
- the elevated set of oxidized methyl groups provides extra protective capacity against, among other things, foreign protein-type agents
- Figure 2 shows the inhibitory effect of oxidized methyl- containing ascorbic acid (code Z) on SARS-COV-2 virus growth using a 1: 4000 dilution of the stock solution in a Vero E6 cell line. Virus density on test plates. (Research report,
- Figure 3 shows the effect of ascorbic acid derivative (Z) with three (E) and two (H) components and an oxidized methyl group on IBV crown virus in the Vero E6 cell line.
- choline is intended to increase the potency of the rapidly donating methyl donor source in the cells.
- Arginine and L-ascorbic acid stimulate the transient accumulation of oxidized methyl groups stored in the weaker bond within the cell's methyl donor pool compared to the more strongly bound ones.
- the additional exogenous excess of the three components enhances the activity of defense through transmethylation in cellular metabolism.
- Their synergistic effect promotes the targeted modification and improvement of the physiological state of the cell associated with the activated methyl group, and the increase of the defense capacity associated with the increase of the transmethylation intensity.
- the beneficial effect outlined is generated by the simultaneous presence of the three components.
- composition according to the invention lies in the fact that, in the knowledge of the connections between the defects of endogenous transmethylation (methylation, demethylation, remethylation) and the development of various diseases, the body "makes available" exogenous intake of the product may be affected and possibly normalized.
- the composition of the present invention comprises methyl donor and methyl acceptor compounds in accordance with the endogenous transmethylation cycle, thereby presumably enabling the body to restore its destabilized internal balance to suit the individual situation. This can be especially important when used for prevention.
- the use of the preparation is therefore not only intended to compensate for the methylation deficiency, but also means a cycle for the maintenance, treatment and automatic restoration of the body and maintenance of the equilibrium according to the laws characteristic of equilibrium reactions according to the needs of the body.
- the present invention is applicable to the control of COVID-19 coronavirus infection, which became worldwide in 2020.
- the example is also a description of the formulation process according to the present invention.
- the moisture content of the raw materials must not exceed 5%.
- the particle size of the raw materials must be set in the range of 100-200 ⁇ m.
- the active ingredients 350 mg of choline bitartrate and 250 mg of L-arginine are mixed and homogenized.
- 420 mg of L-ascorbic acid in the form of a solid powder was added to the two-component homogenized powder mixture, and the mixture was homogenized.
- the second phase of mixing provides a three-component homogeneous composition.
- the mixing of the ingredients must be carried out in a room with an atmosphere of not more than 40% relative humidity.
- a primer composition with a moisture content of not more than 5% does not require the use of an aid to reduce the moisture content.
- the product should be stored airtight (e.g., in a plastic bag or barrel) until reconstitution (tableting, encapsulation).
- the active ingredient content of the tablets and capsules of the preparation should be adjusted to 1 g of useful ingredient per unit weight.
- the homogenized solid mixture is filled into capsules.
- the homogenized .mixture of excipients and active ingredients is tableted under pressure after the addition of a customary formulation carrier and / or excipient .
- the and/or related carriers and excipients required for the formulation are the following: starch, gelatinized starch, cellulose, microcrystalline cellulose or cellulose derivatives, lactose, lactose monohydrate, talc, mannitol, sodium chloride, sodium carbonate, sucrose, maltose, calcium carbonate, colloidal anhydrous silica, stearic acid, magnesium stearate and / or isomalt.
- Corbin, K.D., Zeisel, S.H.. Choline metabolism provides novel insights into nonalcoholic fatty liver disease and its progression., Curr. Opin. Gastroenterol.. 2012, 28,159-65.
- Sard i is,, Stefanovits-Banyai, E, Kocsis, I, et at.: Effect of bioactive compounds of table beet cultivars on alimentary induced fatty livers of rats. Acta Aliment., 2009, 38, 267-280.
- Vali, L Stefanovits-Banyai, E., Szentmihályi, K. et al.: Liver-protecting effects of table beet (Beta vulgaris var. rubra) during ischemia-reperfusion. Nutrition, 2007, 23, 172-178.
- Ascorbic acid inhibits human insulin aggregation and protects against amyloid induced cytotoxicity. Archives of biochemistry and biophysics, 621, 54-62.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The present invention is for use in the control of COVID- 19 coronavirus infection, which became worldwide in 2020. The present invention relates to the methylation of a metabolite, macromolecule, protein, RNA, DNA involved in a multicomponent food supplement with easily mobilizable methyl groups for the control of viral infection, preferably SARS-COV-2 and IBV coronaviruses, a pharmaceutical or pharmaceutical composition comprising at least one methyl donor and at least one methyl acceptor in such a way that that the ratio of methyl donors to methyl acceptors is in accordance with the preferred molar ratios. Definitions : Methyl donor compounds : Organic compounds methylated on N-, S- and 0 heteroatoms where methyl groups thereof transfer into transmethylation cycle after oxidative demethylation. Methyl acceptor compounds : Organic compounds for use in binding methyl (hydroxy methyl ) groups. The invention also relates to a formulation method and a method of administration for use in preparing the compositions.
Description
Food supplement or medicinal or pharmaceutical composition inhibiting virus infection, advantageously infection of SARS- COV-2 and IBV coronaviruses and formulation thereof
I. The subject matter of the invention
The subject matter of the invention is a multi-component, advantageously two or three component food supplement or medicinal or pharmaceutical composition comprising easy mobilizable methyl groups for use in reducing virus infection advantageously infection of SARS-CGV-2 and IBV coronaviruses by changing the "set" of methyl groups of the body and the methylation level of cells by the modification of methylation level of metabolites, macromolecules, proteins, RNA, DNA in the transmethylation cycle of the cells, comprising at least one methyl donor advantageously the following and/or related compounds :
Methyl donors CAS
Choline bitartrate 87-67-2
Formalin 50-00-0
Trimethyl lysine 19253-88-4
Glycine betaine 10743-7
Trigonelline 535-83-1
L-carnitine 541-15-1 and at least one methyl acceptor, advantageously the following and/or related compounds:
Methyl acceptors CAS
L-ascorbic acid 50-81-7
L-arginine 74-79-3
L-homocysteine 6027-13-0
Curcumin 458-37-7
Resveratrol 501-36-0
Gingerol 23513-15-7
Nicotinic acid 59-67-6
Guanidine 113-00-8
Histamine 51-45-6
Glutathione 70-18-8
Carbamide 57-13-6 in such a way that the quotient of molar ratio of the methyl donors and methyl acceptors is higher than "one "and is in 4:1,5 range of molar ratio, advantageously corresponds to 3:2 molar ratio.
Furthermore, the subject matter of the invention is related also to the formulation process of the compositions according to the invention.
The subject matter of the invention is for use in reducing of the worldwide spread COVID-19 coronavirus infection.
Definitions :
Methyl donor compounds: Organic compounds methylated on their N-, S- and 0 heteroatoms where methyl groups thereof transfer into transmethylation cycle after oxidative demethylation.
Methyl acceptor compounds: Organic compounds for use in binding methyl (hydroxy methyl) groups.
II. Prior art, state of the art, mode of action
Results of intensive investigations proved that the maintenance of health and inner balance of body and the inhibition of development of different diseases are associated not only with individual's genetic make-up but also with the nutrition, diet, and other lifestyle choices.
The negative effect of the excessive accumulation of free radicals on the human body and the role of this accumulation in the development of different diseases of plants, animals and humans.
One of the main characters of recommended plant or plant- origin compositions for use in prevention of diseases in the literature is the antioxidant capacity. Beside antioxidant capacity the study of endogenous transmethylation, the methyiation level of living organisms and the physiological effect of the methyl donor compounds in the methyiation cycle, their role in the metabolic process of the body, its regulation, in the supervision of the function of different genes get more and more into the centre of attention.[Corbin and Zeisel, 2012].
Several substitution reactions play a role in the regulation of cellular metabolism, allowing for rapid and reversible regulation of enzyme activity following the synthesis of the enzymes including transmethylation, i.e., the removal and the incorporation of methyl groups. Methyiation, demethylation, and remethylating are common transformations in living organisms. [Sardi, 1996; 2006]
The active form of L-methionine, the S-adenosyl-L-methionine (SAM), has been shown to be a "methyl donor” in endogenous transmethylation reactions [Paik et al. 1975; Szarvas et al. 1986] .
Methyl donors are directly or indirectly involved in the methyiation cycle, however, nucleic acids, proteins, peptides, amino acids, biogenic amines, nor-alkaloids, etc. can be used as acceptor molecules in enzymatic transmethylation reactions. Material quality distribution and quantitative changes of donors and acceptors characterize the physiological state of the biological system. [Sardi and Tyihak, 1998]
The study of the mechanism of action of quaternary ammonium compounds (especially choline), the role of the human body in the metabolism and the regulation of cell function has also become an intensively researched field. [ e.g. Sardi et al. 2009]
Knowing the connections between the defects of methylation and demethylation processes and the development of various diseases, the "available" methyl pool of the organism can be influenced and normalized as needed, all of which can be approached chemically-biochemically and through nutrition.
[Vali et al. 2007/ Sardi 2012/ Blazovics et al. 2012]
The role of methyl donor compounds in human health
Intensive research is underway into the role of mobilizable methyl groups and methyl donor compounds in human health and proliferation. [ e.g., Tyihak et al. 2001].
Several results have been reported for methylated compounds in living organisms, e.g., on its role in the metabolism of choline and in the regulation of cell function. [ e.g. Corbin and Zeisel, 2012]
These published results demonstrate the nutritional-health role of methyl donor compounds available also in plants, [e.g., Mihai et al., 2002; Mann et al., 2006; Mudd et. al., 2007; David et. al., 2009; Kotsopoulos et al., 2010]
On one hand choline has been shown to inhibit cholesterol deposition, to aid metabolism, to use of fatty acids, and to detoxify the body, on the other hand, during the metabolism of the brain, choline is converted to acetylcholine, which plays a role in the transmission of stimuli and in the regulation of the function of nerves coordinating memory and muscle movement. [e.g., Yoshimoto et al. 2004).
People taking long-term choline have a reduced risk of cardiovascular disease [Rajaie es Esmaillzadeh, 2011].
Choline deficiency alters DNA methylation and thus gene expression [Zeisel, 2012]. Choline has also been shown to play an important role in fetal development, so a choline-rich
diet is especially important during pregnancy. [Medici et al. 2014].
Betaine, an oxidation product of choline, potentiates the detoxifying effect of the liver, helps protect against hepatic steatosis, and is a major player in endogenous transmethylation as a methyl donor. [Blazovics et al. 2012]
METHYL DONORS
Choline
Choline is a member of the B-complex, simply because it is not classified as a B-vitamin, because not only can our body get it from an external source, but it can also synthesize it. This requires the involvement of other substances, such as methionine and serine, folic acid, and vitamin B12.
Choline emulsifies fats and cholesterol, so they do not deposit in the liver, gallbladder, or blood vessel walls. As a phosphatidyl-choline, it preserves the integrity of the cell membrane, plays a role in the transfer of information, energy supply and intracellular communication between cells, and participates in the preservation of cellular structures and functions. During the metabolism of the brain, it is converted to acetylcholine, which plays a role in the transmission of stimuli. [Vivekananda et al. 2000]
Adequate choline levels in the brain can provide protection against certain types of dementia, most notably the development of Alzheimer's disease. Several studies have also looked at its effects in patients with pre-existing Alzheimer's disease, and in most experiments, choline supplementation has significantly improved patients' memory. [Tiraboschi et al. 2004].
Through its methyl groups, choline is involved in metabolism as a methyl donor. Choline deficiency in cell culture leads to apoptosis (a form of cell death) or programmed cell death. An
experiment in mice has shown that lecithin (mainly due to the choline it contains) can prevent connective tissue transformation of the liver and cirrhosis of the liver due to excessive alcohol consumption. Thus, lecithin and choline can be especially helpful in combating liver disease. [Baghdasaryan, 2008]
METHYL ACCEPTORS
Ascorbic acid
Along with other vitamins, minerals and nutrients, ascorbic acid acts as an antioxidant in the body. Primarily, it plays a protective role, neutralizing the free radicals that cause ceil damage and mutations due to its antioxidant effect, which causes cell aging or cancerous degeneration. Together with white blood cells, it is involved in protecting the body against infections.
In the development of atherosclerosis, endothelial vasomotor function is abnormal, the potential mechanism of which is increased oxidative stress. Levine et al. (1996) hypothesized that the antioxidant ascorbic acid improves endothelium- dependent arterial dilation in coronary artery disease. Ascorbic acid has been shown to reverse endothelial vasomotor dysfunctions in the brachial circulation of patients with coronary artery disease. These results suggest that increased oxidative stress contributes to endothelial disorder in patients with atherosclerosis and that endothelial dysfunction may respond to antioxidant therapy.
Ascorbic acid contributes to the homeostasis of normal tissues and organs as well as to tissue regeneration. In the brain, ascorbate performs neuromodulatory functions and neutralizes reactive oxygen species formed during synaptic activity and neuronal metabolism. These properties are important because redox imbalance and abnormal protein aggregation play a
central role in the pathogenesis of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease and Huntington's disease, multiple sclerosis, and amyotrophic lateral sclerosis. Thus, ascorbic acid is primarily associated with a reduction in oxidative stress and a reduction in the formation of protein aggregates, which may contribute to a reduction in the cognitive and / or motor impairments observed during neurodegenerative processes [Moretti et al. 2017]
The aggregation of proteins into oligomers and fibrils is associated with several human pathophysiology. Ascorbic acid has been shown to destabilize pre-formed amyloid fibrils in a dose-dependent manner and to protect the human neuroblastoma cell line against amyloid-induced cytotoxicity. Results of Alam et al. (2017) indicate the role of ascorbic acid as a potential molecule in the prevention of human insulin aggregation and several related pathophysiology.
Dietary antioxidants, including ascorbic acid, appear to modify the risk of Alzheimer's disease (AD). [Bowman, 2012]
Low levels of cerebral ascorbic acid increase susceptibility to seizures in mouse models, decreased cerebral ascorbic acid transport, and Alzheimer's disease. These data suggest that avoiding ascorbic acid deficiency may be particularly important in relation to epilepsy and seizures, for example in populations at increased risk of Alzheimer's disease. Exogenous ascorbic acid treatments before and after a seizure reduce the severity of the seizures and the associated neurological damage in rodent models [Warner et al. 2015]. Ascorbic acid has been shown to be a promising memory enhancer in mice. Its protective effect is attributed to its antioxidant properties, which make sensitive brain cells less exposed to oxidative stress, thus reducing brain damage and improving nervous system function, thereby improving memory. It may also influence the treatment of dementia in elderly patients. [Parle and Dhingra, 2003]
Shivavedi et al. (2019) investigated the efficacy of ascorbic acid therapy in the treatment of depressive-like behavior in diabetics. Their results suggest that depression and diabetes mellitus have several pathophysiological properties (Badescu et al. 2016; Zanoveli et al., 2016), including oxidative stress, inflammation, insulin resistance, and overactivation of the HPA axis (Stuart and Baune). , 2012). Ascorbic acid therapy has been found to be very effective in reducing oxidative stress.
L-arginin
Arginine is a semi-essential amino acid involved in the process of nitric oxide formation, which produces nitric oxide directly through nitric oxide synthase enzymes. It is especially important for certain diseases and chronic conditions, such as high blood pressure and type 2 diabetes, as these conditions are usually characterized by an increase in the enzyme that breaks down L-arginine (arginase), which results in a temporary deficiency; this prevents an increase in blood pressure in these conditions and can be partially remedied by increasing L-arginine intake or resolving the disease / disease state. [Wu and Morris, 1998].
Arginine is required by our body in several ways. It is involved in the formation of creatine, which also plays an important role in the body - its lack causes mental retardation. It also affects the production of agmatine, which is a signaling molecule in the body and an intermediate in the urea cycle, along with L-ornithine and L-citrulline.
Arginine helps the body make proteins and stimulates the release of insulin. As part of the nitric oxide cycle, it has
several positive effects on physically active people. The effects of arginine are best attributed to its ability to produce nitric oxide, which affects many other processes in the body. Nitric oxide is an important neurotransmitter, it helps to relax the arteries and thus improves blood circulation, thus helping to prevent cardiovascular disease.
It is also useful in the treatment, of peripheral vascular disease and in all other diseases that cause vasoconstriction and poor blood supply to the limbs. [Tong and Barbul, 2004]
It has a beneficial effect on type 2 diabetes.
One study confirmed that people with type 2 diabetes had lower than healthy levels of L-arginine. [Liu et al. 2016] In the case of inadequate arginine metabolism, L-arginine replacement can help restore molecular balance. Individuals with type 2 diabetes usually experience oxidative stress. A human study demonstrated that arginine supplementation may reduce this negative effect of the disease. [Jablecka et al. 2012; Liu et al. 2016]
Experiments have shown that L-arginine indirectly activates SOD (Superoxide dismutase), and thus a free radical neutralizing protein, which helps to avoid or inhibit free radicals, reduces oxidative damage to the body caused by reactive oxygen species. [Jablecka et al. 2012]
Research has shown that increased nitric oxide levels support the body's immune response. Nitric oxide can stimulate the immune system to fight harmful pathogens. Increasing the level of nitric oxide in the body improves immune responses against unwanted bacteria and viruses. [Popovic et al.2007].
Recent results suggest that increased metabolism of L-arginine in myeloid cells may lead to impaired lymphocyte responses to the antigen during tumor growth and tumor growth. Two enzymes that compete for L-arginine as substrates — arginase and nitric oxide synthase — are critical components of this
lymphocyte suppression pathway, and the metabolic products of these enzymes are important moderators of T cell function. An article by Bronte and Zanovello (2005) focuses on the relevance of L-arginine metabolism in myeloid ceils under physiological and pathological conditions.
Tan et al. (2009) conducted experiments to test the hypothesis that dietary L-arginine supplementation enhances immunity in early weaned piglets. Based on their results, a dietary supplement made with L-arginine enhanced the cellular and humoral immunity of piglets by modulating the production of leukocytes, cytokines, and antibodies. These results indicate that increasing the amount of L-arginine has a beneficial effect on the optimal immune responses of young pigs and may also have important implications for the development of an improved recipe developed for human infants.
Arginine is an important modulator of immune activation, often found in immunotherapeutic systems. However, the mechanism by which arginine may have a positive effect in immunotherapy is unknown. A study by Bansal and Ochoa (2003) details the importance of arginine, its metabolism, and finally its physiological role in critically ill and immunodeficient patients. It has been found that the availability of arginine in critical disease can be regulated by arginase activity, so arginase expression appears to be essential in the regulation of the cellular immune response and the inflammatory process. Arginase plays an important role in the production of precursors of ornithine, proline, and polyamine, all of which are required for cell proliferation and wound healing.
The components of the formulation containing choline, L- ascorbic acid and L-arginine are potentially useful compounds in the cell transmethylation cycle. Transmethylation (Williams, 1966) can modify the level of methylation of metabolites and macromolecules (proteins, RNA, DNA) that are
part of the cycle through rearrangement of the methyl groups of the cell (Park et al., 1980; Park and Paik, 1990; Darnell et al., 1986; Khan et al, 1978; Philips, 2008). Transmethylation plays a role in eliminating the effects of abiotic and biotic stress (Horvath and van Hasselt, 1985; Sardi and Tyihak, 1998; Laszió et al., 1998; Lin and Pearce, 1990; Mullet and Whitsitt, 1996; Tyihak et al., 1989; Nemeth et al. 1938; Albert et al, 1998). Cellular stress responses are reflected in the changes in the amounts of different methyl acceptor and donor metabolites and macromolecules over time (Sardi, 1996),
Upon heat shock, ceils synthesize heat shock proteins with methylated properties (Wang et al, 1981). Methylation of the protective proteins of the genes (histones) and the nucleic acid bases themselves (Paik and Kim, 1967; DeLange et al., 1969; Samson and Cairs, 1977; Karran and Lindahl, 1979; Duerre and Lee, 1974; Tidwell et al., 1968; Lee and Paik, 1972; Paik and Kim, 1968; Dixon, et al., 1975; Honda et al., 1975; DeLange et al., 1973; Hooper et al., 1973; Duerre and Buttz, 1990; Coppard et al., 1983). . The methylation of proteins is able to modify and influence the biological activity in the range of more than 100,000 times the scale.
The choline (chemical name) component of the composition contains three methyl groups attached to a nitrogen atom. Choline is a methyl donor in transmethylation (Michal, 1993; Hanson et al., 2000; Tyihak et al., 1998). Deterministic changes in choline for the treatment of various stress effects have been demonstrated (Sardi, 2006).
III. Solution leading to the subject matter of the invention
L-arginine (chemical name) can efficiently take up the methyl groups of a methyl donor through its guanidino-functional
group (Le and Fujimori, 2012), and the double-bonded carbon pair of L-ascorbic acid has this chemical property. L-arginine and L-ascorbic acid function as methyl acceptors during transmethylation. Methyl acceptors help to regroup methyl groups stored in strong chemical bonds into weaker chemical bonding forms that the ceil can rapidly utilize through targeted methylation to eliminate various stress events.
During the oxidative demethylation of donor metabolites, arginine and L-ascorbic acid can take up oxidized methyl groups (hydroxymethyl groups) temporarily formed from methyl groups as acceptors in a reaction without enzyme catalysis. L- arginine binds oxidized methyl groups at a rate 3-5 times higher than L-ascorbic acid. The ability of these two acceptors to capture oxidized carbon was studied based on their analogous reactions with formaldehyde and examined by FT-IR spectrometry (Fig. 1).
The two graphs in Figure 1 show a model study of the ability of methyl acceptors (L-arginine, L-ascorbic acid) to capture the oxidized methyl group based on FT-IR spectrometric tracing of methyl acceptors with formaldehyde (1.a. Kinetics of Arginine + HCHO reaction; l.b. K-kinetics of L-ascorbic acid + ECHO reaction).
Due to the longer reaction time, the L-arginine content of the formulation induces a decrease in rhe stock of oxidized methyl groups in the cell, compensated by the regulation of transmethylation by intensifying the enzymatic demethylation. In vivo intervention of methyl acceptor dimedone in tissue structure (Sard! 1996; 1998; Laszlo et al., 1998; Nemeth, 2002) was able to increase the amount of oxidized methyl groups in tissues by almost 100%. Elevated levels of the arginine-induced demethylation process of transmethylation fmetabolism are expected to be stabilized by the slow "stealing" role of L-ascorbic acid. The elevated set of oxidized methyl groups provides extra protective capacity
against, among other things, foreign protein-type agents
(e.g., viral protein). The inhibitory effect of the oxidized methyl-binding L-ascorbic acid derivative on SARS-COV-2 and IBV coronaviruses on Vero E6 cell line was also observed in an anonymous, non-accredited cell line experiment (Figures 2 and 3).
Figure 2 shows the inhibitory effect of oxidized methyl- containing ascorbic acid (code Z) on SARS-COV-2 virus growth using a 1: 4000 dilution of the stock solution in a Vero E6 cell line. Virus density on test plates. (Research report,
University of Pecs, Szentagothai Janos Research Center, 2020; report extract).
Figure 3 shows the effect of ascorbic acid derivative (Z) with three (E) and two (H) components and an oxidized methyl group on IBV crown virus in the Vero E6 cell line. (Virological test: Neutralization test with coronavirus, NEBIH, Institute of Veterinary Medicine, 2020; extract from minutes)
Of the three components in the formulation, choline is intended to increase the potency of the rapidly donating methyl donor source in the cells. Arginine and L-ascorbic acid, in turn, stimulate the transient accumulation of oxidized methyl groups stored in the weaker bond within the cell's methyl donor pool compared to the more strongly bound ones. The additional exogenous excess of the three components enhances the activity of defense through transmethylation in cellular metabolism. Their synergistic effect promotes the targeted modification and improvement of the physiological state of the cell associated with the activated methyl group, and the increase of the defense capacity associated with the increase of the transmethylation intensity. The beneficial effect outlined is generated by the simultaneous presence of the three components.
The process of cell transmethylation may play a direct, experimentally unproven role in reducing the activity and
function of foreign proteins. In an "in vitro" cell line study performed under the name anonymous, the effect of the composition on reducing viral proliferation indirectly supports the outlined concept. The characteristic properties and composition of the most preferred ingredients of the formulation are shown in Tables 1 and 2 (Figure 4).
IV . Summary
The essence and advantages of the invention are summarized below.
1. The importance of the composition according to the invention lies in the fact that, in the knowledge of the connections between the defects of endogenous transmethylation (methylation, demethylation, remethylation) and the development of various diseases, the body "makes available" exogenous intake of the product may be affected and possibly normalized. 2. The composition of the present invention comprises methyl donor and methyl acceptor compounds in accordance with the endogenous transmethylation cycle, thereby presumably enabling the body to restore its destabilized internal balance to suit the individual situation. This can be especially important when used for prevention.
3. The use of the preparation is therefore not only intended to compensate for the methylation deficiency, but also means a cycle for the maintenance, treatment and automatic restoration of the body and maintenance of the equilibrium according to the laws characteristic of equilibrium reactions according to the needs of the body.
4. The present invention is applicable to the control of COVID-19 coronavirus infection, which became worldwide in 2020.
V. formulation process,Example
The invention is further illustrated by the following non- limiting examples.
The example is also a description of the formulation process according to the present invention.
To obtain the most preferred three-component composition according to the version of the invention given in the chart above, it is necessary to achieve the chemical purity and exceed 90% purity of the raw materials of the edible ingredients separately. The moisture content of the raw materials must not exceed 5%. The particle size of the raw materials must be set in the range of 100-200 μm. In the first step of the formulation, the active ingredients 350 mg of choline bitartrate and 250 mg of L-arginine are mixed and homogenized. Finally, 420 mg of L-ascorbic acid in the form of a solid powder was added to the two-component homogenized powder mixture, and the mixture was homogenized.
The second phase of mixing provides a three-component homogeneous composition. The mixing of the ingredients must be carried out in a room with an atmosphere of not more than 40% relative humidity. A primer composition with a moisture content of not more than 5%
does not require the use of an aid to reduce the moisture content. After mixing, the product should be stored airtight (e.g., in a plastic bag or barrel) until reconstitution (tableting, encapsulation).
The active ingredient content of the tablets and capsules of the preparation should be adjusted to 1 g of useful ingredient per unit weight.
In the capsule formulation, the homogenized solid mixture is filled into capsules.
For tableting, the homogenized .mixture of excipients and active ingredients is tableted under pressure after the addition of a customary formulation carrier and / or excipient .
The and/or related carriers and excipients required for the formulation are the following: starch, gelatinized starch, cellulose, microcrystalline cellulose or cellulose derivatives, lactose, lactose monohydrate, talc, mannitol, sodium chloride, sodium carbonate, sucrose, maltose, calcium carbonate, colloidal anhydrous silica, stearic acid, magnesium stearate and / or isomalt.
References :
Corbin, K.D., Zeisel, S.H.. Choline metabolism provides novel insights into nonalcoholic fatty liver disease and its progression., Curr. Opin. Gastroenterol.. 2012, 28,159-65.
Sardi, E., Tyihak, E.: Relationship between dimedone concentration and formaldehyde Captured in plant tissues. Acta Biologica., 1998, 4, 291-301.
Paik, W.K., Lee, H.W. et al.: Non-enzymatic methylation of proteins with S-adenosyl-L-methionine. FEBS Lett., 1975, 58, 39-42.
$mms, L, Simon, L P., Trezl, L et al.: S-adenosil methionin, mint formaldehid-prekurzor az allati májszövetekben és ennek összefüggései a biologiai metilézessel. Izotóptechnika, 1986, 29. 247-259.
Sardi, É, Tyihák , E: Change of biotransformation steps of formaldehyde cycle in water-melon plants after infection with Fusarium oxysporum. Acta Biol., 1998, 4, 353-362.
Sard i, is,, Stefanovits-Banyai, E, Kocsis, I, et at.: Effect of bioactive compounds of table beet cultivars on alimentary induced fatty livers of rats. Acta Aliment., 2009, 38, 267-280.
Sardi E, (2013) Termeszetes eredetu metilezo agensek jelentósége az eletminoseg javitasaban. In: Blazovics, Anna; Mezes, Miklos (szerk.) Termeszetes eredetu hatoanyagok a modern orvoslasban. Szent Istvan Egyetemi Kiado, (2013) pp. 90-95
Vali, L, Stefanovits-Banyai, E., Szentmihályi, K. et al.: Liver-protecting effects of table beet (Beta vulgaris var. rubra) during ischemia-reperfusion. Nutrition, 2007, 23, 172-178.
Blázovics, A., Nyirady, P., Romics, I. et al.: How can cancer-associated anemia be moderated with nutritional factors and how do Beta Vulgaris L. ssp. Esculenta Var. Rubra modify the transmethylation reaction in erythrocytes in cancerous patients? "Anemia", book edited by Donald S. Silverberg, ISBN 978-953-51-0138-3. CC BY 3.0 license 2012 pp. 1-23.
Tyihak, E,, Bocsi, J., Timár, J., Rácz, G. and Szende, 8. (2001): Formaldehyde promotes and inhibits the proliferation of cultured tumour and endothelial cells. Cell Proliferation 34: 135-141.
Wlihai D. Niculescu and Steven H. Zeisel (2002) Diet, Methyl Donors and DNA Methylation: Interactions between Dietary Folate, Methionine and Choline· J. Nutr. 132:2333S-2335S,
B. Mann, C. Orihuela, J. Antikainen, G. Gao, J. Sublet!, T. K. Korhonen, E, Tuomanen (2006) Multifunctional Role of Choline Binding Protein G in Pneumococcal Pathogenesis. Infection and Immunity, Vol. 74, No. 2, 821-829,
S H. Mudd, J. T Brosnan, M. E Brosnan, R. L Jacobs, S. P Stabler, R. H Allen, D. E Vance, and C. Wagner (2007) Methyl balance and transmethylation fluxes in humans· Am. J. Clinical Nutrition, 85(1): 19 - 25.
David J. Canty M.S.1 Steven H. Zeisel M.D. (2009) Lecithin and Choline in Human Health and Disease. Nutrition Reviews. Vol. 52 Issue 10, 327 - 339. Published Online: 27 Apr 2009
J Kotsopoulos. S E Hankinson. S S Tworoger (2010) Dietary betaine and choline intake are not associated with risk of epithelial ovarian cancer. European Journal of Clinical Nutrition 64(1): 111-114
Corbin K.D.. Zeisel S.H. (2012) Choline metabolism provides novel insights into nonalcoholic fatty liver disease and its progression., Curr Opin Gastroenterol. 28(21:159-65.
Yoshimoto M. Waki A. Obata A. Furukawa T. Yonekura Y. Fuiibavashi Y. Chang JC. Gross EA. Swenberg JA. Barrow CS. (2004) Radiolabeled choline as a proliferation marker: comparison with radiolabeled acetate, Nuclear Medicine and Biology, 31(7):859-65
Raiaie S. Esmaillzadeh A. (2011) Dietary choline and betaine intakes and risk of cardiovascular diseases: review of epidemiological evidence. ARYA Atheroscler.7(2):78-86.
Zeisel S.H. (2012) Dietary choline deficiency causes DNA strand breaks and alters epigenetic marks on DNA and histones. Mutat Res. 1;733(1-2):34-8.
Medici V, Shibata NM, Kharbanda KK, Islam MS Keen CL, Kim K, Tillman B, French SW, Halsted CH, LaSalle JM. (2014) Maternal choline modifies fetal liver copper, gene expression, DNA methylation, and neonatal growth in the tx-j mouse model of Wilson disease. Epigenetics. 1 :9(2):286-96. doi: 10.4161 /epi.27110
Blazovics A., Nyiradi P., Romics I., Szúcs M., Horvath A., Szilvas A., Szekely E., Szentmihalyi K., Beko G., Sardi E. (2012) How Can Cancer-Associated Anemia Be Moderated with Nutritional Factors and How Do Beta Vulgaris L. Ssp. Esculenta Var. Rubra Modify the Transmethylation Reaction in Erythrocytes in Cancerous Patients? Anemia (Ed.: Donald S. Silverberg), Chapters: 7 p. 93-114
Vivekananda J. Awasthi V. Awasthi S. Smith DB. King RJ (2000) Hepatocyte growth factor is elevated in chronic lung injury and inhibits surfactant metabolism; American Journal of Physiology - Lung Cellular & Molecular Physiology. 278(2)L382-92
Tiraboschi P, Hansen LA, Masliah E, Alford M, Thai LJ, Corey-Bloom J. (2004) Impact of APOE genotype on neuropathologic and neurochemical markers of Alzheimer disease. Neurology 62:1977- 1983
Baghdasarvan A, Fickert P, Fuchsbichler A. Silbert D, Gumhold J, Horl G, Langner C, Moustafa T, Halilbasic E, Claudel T, Trauner M. (2008) Role of hepatic phospholipids in development of liver injury in Mdr2 (Abcb4) knockout mice. Liverjnt, 28(7):948-58
Levine, G. N., Frei, B., Koulouris, S. N., Gerhard, M. D., Keaney Jr, J. F., & Vita, J. A. (1996). Ascorbic acid reverses endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation, 93(6), 1107-1113.
Moretti, M., Fraga, D. B., & Rodrigues, A. L. S. (2017). Preventive and therapeutic potential of ascorbic acid in neurodegenerative diseases. CNS Neuroscience & Therapeutics, 23(12), 921-929.
Alam, P., Beg, A. 2., Siddiqi, M. K., Chaturvedi, S. K., Rajpoot, R. K., Ajmal, M. R., ... & Khan, R. H.
(2017). Ascorbic acid inhibits human insulin aggregation and protects against amyloid induced cytotoxicity. Archives of biochemistry and biophysics, 621, 54-62.
Bowman, G. L. (2012). Ascorbic acid, cognitive function, and Alzheimer's disease: a current review and future direction. Biofactors, 38(2), 114-122.
Warner, T. A., Kang, J. Q,, Kennard, J. A., & Harrison, F. E. (2015). Low brain ascorbic acid increases susceptibility to seizures in mouse models of decreased brain ascorbic acid transport and Alzheimer's disease. Epilepsy research, 110, 20-25.
Parle, M., & Dhingra, D. (2003). Ascorbic acid: a promising memory-enhancer in mice. Journal of pharmacological sciences, 93(2), 129-135.
Shivavedi, N., Tej, G. N. V. C., Neogi, K., & Nayak, P. K. (2019). Ascorbic acid therapy: a potential strategy against comorbid depression-like behavior in streptozotocin-nicotinamide-induced diabetic rats. Biomedicine & Pharmacotherapy, 109, 351-359.
S. Badescu, C. Tataru, L. Kobylinska, E. Georgescu, D. Zahiu, A. Zagrean, L. Zagrean (2016) The association between diabetes mellitus and depression. J. Med. Life, 9 (2) (2016), pp. 120-125
J.M. Zanoveli, Hd. Morais, I.C. Dias, A.K. Schreiber, C.P. Souza, J.M. Cunha (2016) Depression associated with diabetes: from pathophysiology to treatment. Curr. Diab. Rev., 12 (3) (2016), pp. 165- 178
4
M.J. Stuart, B.T. Sauna (2012) Depression and type 2 diabetes: inflammatory mechanisms of a psychoneuroendocrine co-morbidity. Neurosci. Biobehav. Rev., 36 (1), pp. 658-676
Wu, G., & Morris Jr, S. M. (1998). Arginine metabolism: nitric oxide and beyond. Biochemical Journal, 336(1), 1-17.
Betty C. Tong and Adrian Barbul (2004) Cellular and Physiological Effects of Arginine. Mini-Reviews in Medicinal Chemistry, 2004, 4, 823-832
Liu, X., Gao, J., Chen, J., Wang, Z., Shi, Q., Man, H., ... & Wang, W. (2016). identification of metabolic biomarkers in patients with type 2 diabetic coronary heart diseases based on metabolomic approach. Scientific reports, 6, 30785.
Jablecka, A., Bogdanski, P., Baicer, N., Cieslewicz, A., Skoluda, A., & Musialik, K, (2012). The effect of oral L-arginine supplementation on fasting glucose, HbA1c, nitric oxide and total antioxidant status in diabetic patients with atherosclerotic peripheral arterial disease of lower extremities. Eur Rev Med Pharmacol Sci, 16(3), 342-50.
Popovic, P. J., Zeh III, H, J., & Ochoa, J. B. (2007). Arginine and immunity. The Journal of nutrition, 137(6), 1681S-1686S.
Bronte, V., & Zanoveilo, P. (2005). Regulation of immune responses by L-arginine metabolism. Nature Reviews Immunology, 5(8), 641-654.
Nieves dr, C., & Langkamp-Henken, B. (2002). Arginine and immunity: a unique perspective. Biomedicine & pharmacotherapy, 56(10), 471-482.
Tan, B., Li, X. G., Kong, X., Huang, R., Ruan, Z., Yao, K., ... & Wu, G. (2009). Dietary L-arginine supplementation enhances the immune status in early-weaned piglets. Amino acids, 37(2), 323-331.
Bansal, V., & Ochoa, J. B, (2003). Arginine availability, arginase, and the immune response. Current Opinion in Clinical Nutrition & Metabolic Care, 6(2), 223-228.
Williams J.N. (1966) Enzymes of transmethylation. In: Bruns F.H. et al. (eds) Enzyme. Handbuch der Physiologisch- und Pathologisch-Chemischen Analyse (Für Ärzte, Biologen und Chemiker), vol 6 l b. Springer, Berlin, Heidelberg, pp. 203-208. https://doi.org/10.1007/978-3-662-30541-6_3
W.K. Paik, E. Polastro, S. Kim, Cytochrome c methylation: enzymology and biologic significance, in Current Topics in Cellular Regulation, 16, B.L. Horecker, E.R. Stadtman, Eds., Academic Press, New York, 1980.
I.K. Park, W.K. Paik, The Occurrence and Analysis of Methylated Amino Acids, in Protein Methylation, W.K. Paik, S. Kim, Eds., CRC Press Inc., Boca Raton, Florida, 1990, 1.
J. Darnell, H. Lodish, D. Baltimore, Molecular cell biology, Scientific American Books, New York, 1986, 511.
M. S. N. Khan, M. Salim, B. E, H. Maden, Extensive homologies between the methylated nucleotide sequences in several vertebrate rRNAs, Biochem. J., 169, (1978), 531.
Phillips, I. (2008) The rote of methylation in gene expression, Nature Education 1(1):116
J. Horvath, P. R. Van Hasselt, Inhibition of chilling induced phytooxidative damage in leaves of Cucumis sativus L. by treatment with aminoalcohols, Planta, 164, (1985), 83.
E Sárdi, E. Tyihák, Change of biotransformation steps of formaldehyde cycle in water-melon plants after infection with Fusarium oxysporum, Acta Biologica Hungarica, 49 (2-4), (1998), 353.
Sardi, E es Tyihak, E. (1998) Relationship between dimedone concentration and formaldehyde Captured in plant tissues. Acta biologica hungarica 49 : 2-4 pp. 291-301.
I. Laszlo, E. Szoke, E. Tyihak, Relationship between abiotic stress and formaldehyde concentration in tissue culture of Datura innoxia Mill., Plant Growth Regulation, 25, (1998), 195.
S. S. Lin, R. S. Pearce, Changes in lipids of bean seeds and corn (Zea mays ) caryopses aged in contrasting enviroments, Ann. Bot. 62, (1990), 451.
J. E. Mullet, M. S. Whitsitt, Plant cellular responses to water deficit, in Plant Groth Regul., ed.:
E. Belhassen, 20, (1996), 119.
E. Tyihak, Z. Kiraiy, G. Gullner, T. Szarvas, Temperature-dependent Formaldehyde Metabolism in Bean Plants.The Heat Shock Response, Plant Sci., 59,
(1989), 133.
Zs.l. Nemeth, L. Albert, Sz. Varga, Changes in formaldehyde contents of germinating acorns of Quercus cerris L. under low temperature stress conditions, Acta Biologica Hungarica, 49 (2-4), (1998), 369.
L. Albert, Zs.l. Nemeth, Sz, Varga, The effect of heat shock on the formaldehyde cycle in germinating acorns of European Turkey oak, Acta Biologica Hungarica, 49 (2-4), (1998), 363.
Sardi, E. (1996) A formaldehid es egyes generatorainak tanulmanyozasa Fusarium oxisporum f. sp. niveum-mal fertozott gorog-dinnye novenyeken 127 p. PhD Disszertacio (MTA)
C Wang, R H Gomer and E Lazarides (1981): Heat shock proteins are methylated in avian and mammalian cells. Proc Natl Acad Sci USA, 78(6), pp. 3531-3535.
W.K. Paik, S. Kim, ε-N-Dimethyllysine in histones, Biochem. Biophys. Res. Commun., 27,
(1967), 479.
R.J. DeLange, D.M. Fambrough, E.L. Smith, J. Bonner, Calf and pea histone IV: comparison with the homologous calf thymus histone, J. Biol. Chem., 244, (1969), 5669.
L. Samson, J. Cairs, A new pathway for DNA repair in Escherichia coli, Nature, 267, (1977),
281.
P. Karran, T. Lindahl, Adaptive response to alkylating agents involves alteration in situ of F- methylguanine residues in DNA, Nature, 280, (1979), 76.
J.A. Duerre, C.T. Lee, In vivo methylation and turnover of rat brain histones, J. Neurochem., 23,
(1974), 541.
T. Tidwell, V.G. Allfrey, A.E. Mirsky, The methylation of histones duringregeneration of the liver,
J. Biol. Chem., 243, (1968), 707.
H.W. Lee, W.K. Paik, Histone methylation during hepatic regeneration in rat, Biochim. Biophys.
Acta, 277, (1972), 107.
W.K. Paik, S. Kim, Protein methylase I, J. Biol. Chem., 243, (1968), 2108.
G. H. Dixon, E.P.i. Candldo, B. M. Honda, A. J. Louie, A. R. Macleod, M. T. Sung, The biological roles of post-synthetic modifications of basic nuclear proteins, Ciba Found, Symp., 28, (1975), 229
B. M. Honda, G. H, Dixon, E.P.M. Candido, Sites of in vivo histone methylation in developing trout testis, J. Biol. Chem., 250, (1975), 8681.
11 J. DeLange, J, A. Hooper, E L. Smith, Histone III. 111. Sequence studies on the cyanogen bromide peptides, complete amino acid sequence of calf thymus histone III., J. Biol. Chem., 248, (1973), 3261.
J. A. Hooper, E, L. Smith, K. R. Sommer, R. Chalkley, Histone ill. VI. Amino acid sequence of histone III. of the testes of the carp, Letiobus bubalus, J. Biol. Chem., 248, (1973), 3275.
J. A. Duerre, H. R. Buttz, Histone methylation and gene regulation, in Protein Methylation, eds.
W. K. Paik and S. Kim, CRC Press, Boca Raton, Florida, 1990, 125.
N. J. Coppard, B. F. C. Clark, F. Cramer, Methylation of elongation faktor 1α in mouse 3T3B and 3T3B/SV40 cells, FEBS Let., 164, (1983), 330
G.Michal , Biochemical pathways, Biochemica, Boehringer Mannheim GrnbH,Wiirzburg, Germany, 3rd ed„ Part 1, 1993.
A.D. Hanson, D. A. Gage, Y. S. Hill, Plant one-carbon metabolism and its engineering, Trends in Plant Science, 5 (5), (2000), 206.
E, Tyihak, L. Albert, Zs. I. Nemeth, Gy. Katay, Zs. Kiraly-Veghely, B. S¾nde, Formaldehyde cycle and the natural formaldehyde generators and captures, Acta Biologlca Hungarica, 49 (2-4), (1998) 225.
Sardi, E. (2006) A novenyek betegseg-ellenal!osaga es az endogen transzmetilezesi folyamatok kapcsolata. DSc doktori disszertacio (MTA Doktora) Relationship between disease resistance of plants and endogenous transmethylation processes. DSc doctoral dissertation (Doctor of the Hungarian Academy of Sciences)
Daniel D Le and Danica Galonic Fujimori (2012): Protein and nucleic acid methylating enzymes: mechanisms and regulation, Curr Opin Chem Biol 16(5-6), pp. 507-515,
Nemeth Zs I (2002): A formaldehid es termeszetes generatorai, mint a kornyezeti hatasok jelzo molekulai a csertolgy ontogenezisenek korai szakaszaiban (Ph D disszertacio), Nyugat-Magyarorszagi
Egyetem, Erdomernoki Kar, p. 101. (Formaldehyde and its natural generators as signaling molecules in the early stages of oak ontogenesis (Ph D dissertation), University of West Hungary, Faculty of Forestry) p. 101.
Claims
CLAIMS l.A multi-component, food supplement or medicinal or pharmaceutical composition comprising easy mobilizable methyl groups for use in reducing virus infection advantageously infection of SARS-COV-2 and IBV coronaviruses by changing the "set" of methyl groups of the body and the methylation level of cells by the modification of methylation level of metabolites, macromolecules, proteins, RNA, DNA in the transmethylation cycle of the cells, characterized in comprising at least one methyl donor in such a way that the quotient of molar ratio of the methyl donors and methyl acceptors is higher than "one "and is in 4:1,5 range of molar ratio.
2. Composition according to claim 1 characterized in, that the composition is two or three component composition, and the quotient of molar ratio of the methyl donors and methyl acceptors is 3:2.
3.Composition according to any one of claims 1 and 2 characterized in, that methyl donors are following and/or related compounds:
Choline bitartrate 87-67-2
Formalin 50-00-0
Trimethyl lysine 19253-88-4 Glycine betaine 10743-7 Trigonelline 535-83-1 L-carnitine 541-15-1
4.Composition according to any one of claims 1 and 2 characterized in, that methyl acceptors are following and/or related compounds:
L-ascorbic acid 50-81-7
L-arginine 74-79-3
L-homocysteine 6027-13-0
Curcumin 458-37-7
Resveratrol 501-36-0
Gingerol 23513-15-7
Nicotinic acid 59-67-6
Guanidine 113-00-8
Histamine 51-45-6
Glutathione 70-18-8
Carbamide 57-13-6
5. Composition according to any one of claims 1 to 4 characterized in comprising choline bitartrate as methyl donor and L-ascorbic acid and L-arginine as methyl acceptors and the quotient of molar ratio of the methyl donors and methyl acceptors is 3:2.
6. Composition according to any one of claims 1 to 5 characterized in, that the composition is tablet, inhalation powder, capsule, cone, or injection solution.
7.Composition according to any one of claims 1 to 6 characterized in, that it can be administered orally or buccaliy or sublingually or rectally or by inhalation or parenterally or intravenously.
8. Oral composition according to any one of claims 1 to 5 characterized in, that it is solid, comprising the methyl donors and methyl acceptors according to any one of claims 1 to 5 and it is formulated in capsules.
9.Oral composition according to any one of claims 1 to 5 characterized in, that it is solid, comprising the methyl
donors and methyl acceptors according to any one of claims 1 to 5, it is formulated in tablets, comprising pharmaceutically acceptable inert, solid carrier and/or excipient.
10. Oral composition according to claim 9 characterized in, that it is tablet, comprising following pharmaceutically acceptable carriers and/or excipients for use in formulation: starch, gelatinized starch, cellulose, microcrystalline cellulose or cellulose derivatives, lactose, lactose monohydrate, talc, mannitol, sodium chloride, sodium carbonate, sucrose, maltose, calcium carbonate, colloidal anhydrous silica, stearic acid, magnesium stearate and / or isomalt.
11. Formulation process for preparation of composition according to any one of claims 1 to 10 characterized in, that the active ingredients and the pharmaceutically acceptable inert solid or liquid carriers and excipients are mixed in a proper ratio and afterwards formulated to the food supplement or medicinal or pharmaceutical composition according to any one of claims 1 to 10 by using the standard formulation methods.
12. Formulation process for preparation of solid, oral composition according to any one of claims 6 to 11 characterized in as given below:
To obtain the most preferred three-component composition according to the version of the invention given in the chart above, it is necessary to achieve the chemical purity and exceed 90% purity of the raw materials of the edible ingredients separately. The moisture content of the raw materials must not exceed 5%. The particle size of the raw materials must be set in the range of 100-200 mih. In the first step of the formulation, the active ingredients 350 mg of choline bitartrate and 250 mg of L-arginine are mixed and homogenized.
Finally, 420 mg of L-ascorbic acid in the form,of a solid powder was added to the two-component homogenized powder mixture, and the mixture was homogenized.
The second phase of mixing provides a three-component homogeneous composition.
The mixing of the ingredients must be carried out in a room with an atmosphere of not more than 40% relative humidity. A primer composition with a moisture content of not more than 5% does not require the use of an aid to reduce the moisture content. After mixing, the product should be stored airtight (e.g., in a plastic bag or barrel) until reconstitution (tableting, encapsulation). The active ingredient content of the tablets and capsules of the preparation should be adjusted to 1 g of useful ingredient per unit weight.
In the capsule formulation, the homogenized solid mixture is filled into capsules.
For tableting, the homogenized mixture of excipients and active ingredients is tableted under pressure after the
addition of a customary formulation carrier and / or excipient.
The and/or related carriers and excipients required for the formulation are the following: starch, gelatinized starch, cellulose, microcrystailine cellulose or cellulose derivatives, lactose, lactose monohydrate, talc, mannitol, sodium chloride, sodium carbonate, sucrose, maltose, calcium carbonate, colloidal anhydrous silica, stearic acid, magnesium stearate and / or isomalt.
13. Composition according to any one of claims 1 to 12 characterized in, that it is for use in reducing virus infection.
14. Composition according to claim 13 characterized in, that it is for use in reducing Covid-19 virus infection caused by the SARS-COV-2 coronavirus.
15. Composition according to claim 13 characterized in, that it is for use in reducing bird flu virus infection caused by the IBV coronavirus.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP21890365.6A EP4210505A2 (en) | 2020-09-11 | 2021-11-10 | Food supplement or medicinal or pharmaceutical composition inhibiting virus infection, advantageously infection of sars-cov-2 and ibv coronaviruses and formulation thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HUP-2000298 | 2020-09-11 | ||
HU2000298A HUP2000298A1 (en) | 2020-09-11 | 2020-09-11 | Food supplement or medicinal or pharmaceutical composition to control viral infection, particularly sars-cov-2 and ibv coronaviruses and their formulation |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2022112806A2 true WO2022112806A2 (en) | 2022-06-02 |
WO2022112806A3 WO2022112806A3 (en) | 2022-09-01 |
Family
ID=89993188
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/HU2021/000014 WO2022112806A2 (en) | 2020-09-11 | 2021-11-10 | Food supplement or medicinal or pharmaceutical composition inhibiting virus infection, advantageously infection of sars-cov-2 and ibv coronaviruses and formulation thereof |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP4210505A2 (en) |
HU (1) | HUP2000298A1 (en) |
WO (1) | WO2022112806A2 (en) |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000025764A2 (en) * | 1998-10-30 | 2000-05-11 | Merck Patent Gmbh | Compositions for the treatment and prevention of cardiovascular diseases |
EP1513419A2 (en) * | 2002-06-19 | 2005-03-16 | N.V. Nutricia | Method and composition for treating or preventing catabolism or stimulating anabolism in a mammal undergoing metabolic stress |
WO2018104909A2 (en) * | 2016-12-09 | 2018-06-14 | St. Jude Children's Research Hospital | Dna methylation profiling for t-cell immunotherapy |
WO2021202245A1 (en) * | 2020-04-02 | 2021-10-07 | Egaceutical Corporation | Viral treatment regimens |
-
2020
- 2020-09-11 HU HU2000298A patent/HUP2000298A1/en unknown
-
2021
- 2021-11-10 WO PCT/HU2021/000014 patent/WO2022112806A2/en unknown
- 2021-11-10 EP EP21890365.6A patent/EP4210505A2/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
WO2022112806A3 (en) | 2022-09-01 |
EP4210505A2 (en) | 2023-07-19 |
HUP2000298A1 (en) | 2022-03-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Chitimus et al. | Melatonin’s impact on antioxidative and anti-inflammatory reprogramming in homeostasis and disease | |
Perše | Cisplatin mouse models: Treatment, toxicity and translatability | |
Horning et al. | Manganese is essential for neuronal health | |
Yin et al. | Rapidly increased neuronal mitochondrial biogenesis after hypoxic-ischemic brain injury | |
EP2756757B1 (en) | Preparation and compositions of zero-valent sulphur having high bioavailability, and uses thereof | |
Saxena et al. | Superoxide dismutase as multipotent therapeutic antioxidant enzyme: Role in human diseases | |
US9623042B2 (en) | Combination preparation for improving sperm quality | |
CN104918613B (en) | Cardiovascular event is treated or prevented by giving colchicine derivative | |
CN1985993B (en) | Compound preparation for enhancing memory | |
Li et al. | Dietary luteolin protects against renal anemia in mice | |
ES2346859T3 (en) | GLUTATION PRECURSORS FOR THE TREATMENT OF NEUROSIQUIATRIC DISORDERS. | |
CN104053368B (en) | Resist the compositionss of cell injury effect | |
Pinho et al. | Gold nanoparticle-based therapy for muscle inflammation and oxidative stress | |
US10980791B1 (en) | Multi-component nutritional supplement formulations and treatment regimen | |
ES2906614T3 (en) | Agent to prevent or ameliorate deterioration of brain function | |
JP6122652B2 (en) | Proteasome activator | |
EP2065045A1 (en) | Antioxidant for preventing and treating diseases caused by oxidative stress | |
EP4210505A2 (en) | Food supplement or medicinal or pharmaceutical composition inhibiting virus infection, advantageously infection of sars-cov-2 and ibv coronaviruses and formulation thereof | |
US20150064263A1 (en) | Compositions and methods for reduction of mercury toxicity | |
JP2014502633A (en) | Antiviral agent | |
AU2015101752A4 (en) | Composition for mood and/or cognitive function support | |
FI122450B (en) | A composition for the treatment of sterile inflammation | |
CN103108647B (en) | Brain function enhancement composition and method for enhancing brain function | |
CN104619316B (en) | For reducing the pharmaceutical composition of N- trimethylamine oxide level | |
CN109379887A (en) | Based on carnosine-magnesium complex topical compositions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021890365 Country of ref document: EP Effective date: 20230411 |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21890365 Country of ref document: EP Kind code of ref document: A2 |